Sponsor
1 Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial The Lancet Oncology, April 24, 2013
2 Egg consumption in relation to risk of cardiovascular disease and diabetes: a systematic review and meta-analysis American Journal of Clinical Nutrition, May 21, 2013 Evidence Based Medicine Review Article
3 Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis The Lancet, May 20, 2013
4 The Center for Technology and Aging launches online mHealth toolkit Healthcare IT News, May 3, 2013
5 Obamacare is on the horizon, but will enough people sign up? Reuters Health News, May 7, 2013
6 Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab Clinical Cancer Research, May 8, 2013
7 Virtual health care gaining ground USA Today, May 7, 2013
8 Shoulder mobility, muscular strength, and quality of life in breast cancer survivors with and without Tai Chi Qigong training Evidence-based Complementary and Alternative Medicine , May 6, 2013 Review Article
9 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, May 3, 2013
10 Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial The Lancet Oncology, May 3, 2013
Sponsor
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor